Clinical Trial Update: Trial of Gemcitabine With or Without MSC1936369B in Pancreatic Cancer [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial evaluating gemcitabine with or without MSC1936369B in pancreatic adenocarcinoma has completed and results were posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Adenocarcinoma

Drugs mentioned

• Gemcitabine (Gemcitabine)
• MSC1936369B (MSC1936369B)

Snippet

Sponsor: EMD Serono | Conditions: Pancreatic Adenocarcinoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2017-06-23